Emerging Medical Therapies in Rosacea: A Narrative Review
- PMID: 37824060
- PMCID: PMC10689680
- DOI: 10.1007/s13555-023-01048-1
Emerging Medical Therapies in Rosacea: A Narrative Review
Abstract
Rosacea is a chronic inflammatory disease with a multifactorial pathogenesis. The wide spectrum of clinical phenotypes, including erythema, telangiectasia, inflammatory papules and pustules, and phyma, demand an individualized approach to treatment. This narrative review offers an updated reference for rosacea management by covering the latest developments in both topical and systemic treatments, including data from newly approved therapies, updates to current treatment modalities and ongoing clinical trials. Although use of benzoyl peroxide as a treatment for rosacea has typically been limited due to irritation, the improved tolerability due to microencapsulation of benzoyl peroxide 5% cream provides a new therapeutic option for patients with rosacea. Minocycline foam and topical ivermectin cream add to our armamentarium of treatment options, particularly for inflammatory papules and pustules. Sarecycline has a narrower spectrum of antibacterial activity, which might reduce the development of antibiotic resistance and disruption of the microbiome compared to other oral antibiotics. Brimonidine gel and oxymetazoline cream provide topical options for redness and flushing. There is emerging evidence about the role of hydroxychloroquine and intradermal botulinum toxin A, which may improve rosacea through their effects on mast cells. The clinical trials pipeline includes agents with a variety of mechanisms, including mast cell stabilization, antimicrobial, anti-inflammatory, and vasoconstrictive effects. However, the clinical pipeline for rosacea appears limited, and there remain important unmet needs for patients with more recalcitrant rosacea or phymatous disease. In addition, there is a need for comparative effectiveness studies to identify the highest value treatment approaches for patients with rosacea.
Keywords: Benzoyl peroxide; Botulinum toxin; Brimonidine; Hydroxychloroquine; Ivermectin; Microencapsulation; Minocycline; Oxymetazoline; Rosacea; Sarecycline.
© 2023. The Author(s).
Conflict of interest statement
John S. Barbieri has received consulting fees from Dexcel Pharma for work unrelated to the present study. James Choe has nothing to disclose.
Similar articles
-
Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape.Drugs. 2024 Mar;84(3):275-284. doi: 10.1007/s40265-024-02003-w. Epub 2024 Feb 29. Drugs. 2024. PMID: 38418773 Free PMC article. Review.
-
Rosacea: An Update in Diagnosis, Classification and Management.Skin Therapy Lett. 2021 Jul;26(4):1-8. Skin Therapy Lett. 2021. PMID: 34347259
-
Advances in pharmacotherapy for rosacea: what is the current state of the art?Expert Opin Pharmacother. 2022 Nov;23(16):1845-1854. doi: 10.1080/14656566.2022.2142907. Epub 2022 Nov 5. Expert Opin Pharmacother. 2022. PMID: 36330970 Review.
-
Interventions for rosacea.Cochrane Database Syst Rev. 2015 Apr 28;2015(4):CD003262. doi: 10.1002/14651858.CD003262.pub5. Cochrane Database Syst Rev. 2015. PMID: 25919144 Free PMC article. Review.
-
A Review of the Diagnostic and Therapeutic Gaps in Rosacea Management: Consensus Opinion.Dermatol Ther (Heidelb). 2024 Feb;14(2):271-284. doi: 10.1007/s13555-023-01087-8. Epub 2024 Jan 9. Dermatol Ther (Heidelb). 2024. PMID: 38194021 Free PMC article.
Cited by
-
Prescriber Phenotypes: Variability in Topical Rosacea Treatment Patterns Among United States Dermatologists.J Clin Med. 2024 Oct 21;13(20):6275. doi: 10.3390/jcm13206275. J Clin Med. 2024. PMID: 39458225 Free PMC article.
-
Important Roles of Interleukin-36, Interleukin-37, and Interleukin-38 Cytokines in the Pathogenesis of Rosacea.Indian J Dermatol. 2024 May-Jun;69(3):232-237. doi: 10.4103/ijd.ijd_470_23. Epub 2024 Jun 26. Indian J Dermatol. 2024. PMID: 39119329 Free PMC article.
-
Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea.Front Immunol. 2024 Jul 29;15:1403798. doi: 10.3389/fimmu.2024.1403798. eCollection 2024. Front Immunol. 2024. PMID: 39136023 Free PMC article. Review.
References
-
- Mc Aleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol. 2009;144:663–671. - PubMed
-
- Oussova T, New drug application approval letter for Epsolay (benzoyl peroxide) cream. US Food and Drug Administration. April 22, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/214510Orig.... Accessed 20 July 2023.
-
- Sugarman J, Baldwin H, Bhatia N. Efficacy of microencapsulated benzoyl peroxide (E-Bpo) cream, 5% in elderly rosacea patients. SKIN J Cutan Med. 2021;5:s27–s27. doi: 10.25251/skin.5.supp.27. - DOI
Publication types
LinkOut - more resources
Full Text Sources